Effect of trifunctional bispecific antibody (BiLu) on GVHD and GVT induction by C57BL/6 spleen cells in mice inoculated with a sublethal dose of melanoma cells
. | . | Cause of death, no. . | . | . | |
|---|---|---|---|---|---|
| Effector cells and BiLu pretreatment . | Median survival, d (range) . | Tumor . | GVHD . | No. disease-free survivors . | |
| No splenocytes | |||||
| No BiLu pretreatment | 33 (24-> 212) | 60 | NA | 7 | |
| BiLu pretreatment | > 212 (24-> 212) | 3 | NA | 7 | |
| Splenocytes | |||||
| No BiLu pretreatment | 20 (14-> 212) | 3* | 23 | 1 | |
| BiLu pretreatment | > 212 (25-> 212) | 4* | 5 | 16 | |
. | . | Cause of death, no. . | . | . | |
|---|---|---|---|---|---|
| Effector cells and BiLu pretreatment . | Median survival, d (range) . | Tumor . | GVHD . | No. disease-free survivors . | |
| No splenocytes | |||||
| No BiLu pretreatment | 33 (24-> 212) | 60 | NA | 7 | |
| BiLu pretreatment | > 212 (24-> 212) | 3 | NA | 7 | |
| Splenocytes | |||||
| No BiLu pretreatment | 20 (14-> 212) | 3* | 23 | 1 | |
| BiLu pretreatment | > 212 (25-> 212) | 4* | 5 | 16 | |
F1 mice were inoculated with B16-EpCAM melanoma cells (5 × 103) 24 hours after conditioning with 4 Gy TBI. One day later, 30 × 106 naive C57 splenocytes were given intraperitoneally with or without pretreatment with BiLu (10 μg per mouse). P values are for the comparison of tumor- and GVHD-related death as well as for disease-free survivors with or without BiLu treatment. Unless otherwise indicated, P < .001.
NA indicates not applicable.
P = .005